Table 2.
T2D susceptibility loci with sex-differentiated evidence of association
| SNP | Chr | Position (Build 36) |
Allelesa | Risk allele frequencyb |
Nearby gene | Male meta-analysis: up to 20,219 cases and 54,604 controls |
Female meta-analysis: up to 14,621 cases and 60,377 controls |
Sex-differentiated meta-analysis: up to 34,840 cases and 114,981 controls |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Risk | Other | OR (95% CI) | P-value | OR (95% CI) | P-value | Association P-value | Heterogeneity P-value | |||||
| New loci identified through sex-differentiated meta-analysis achieving genome-wide significance (P < 5×10 −8) | ||||||||||||
| rs11063069 | 12 | 4,244,634 | G | A | 0.21 | CCND2 | 1.12 (1.08–1.16) | 1.1×10−9 | 1.04 (1.00–1.09) | 3.6×10−2 | 9.8×10−10 | 1.3×10−2 |
| rs8108269 | 19 | 50,850,353 | G | T | 0.31 | GIPR | 1.05 (1.02–1.08) | 3.7×10−3 | 1.10 (1.06–1.14) | 2.2×10−7 | 2.1×10−8 | 5.7×10−2 |
| Other loci with nominally significant evidence (P < 0.05) of heterogeneity in allelic odds ratios between sexes | ||||||||||||
| rs163184 | 11 | 2,803,645 | G | T | 0.50 | KCNQ1 | 1.12 (1.09–1.16) | 8.5×10−15 | 1.05 (1.01–1.08) | 7.8×10−3 | 2.4×10−15 | 1.3×10−3 |
| rs17168486 | 7 | 14,864,807 | T | C | 0.19 | DGKB | 1.15 (1.11–1.19) | 6.5×10−13 | 1.06 (1.02–1.11) | 5.2×10−3 | 1.2×10−13 | 6.8×10−3 |
| rs3923113 | 2 | 165,210,095 | A | C | 0.63 | GRB14 | 1.05 (1.01–1.08) | 4.9×10−3 | 1.11 (1.08–1.15) | 1.8×10−9 | 2.6×10−10 | 8.0×10−3 |
| rs243088 | 2 | 60,422,249 | T | A | 0.45 | BCL11A | 1.10 (1.06–1.13) | 6.5×10−10 | 1.04 (1.00–1.07) | 2.8×10−2 | 4.7×10−10 | 1.2×10−2 |
Chr, chromosome; OR, odds ratio; CI, confidence interval.
a
Alleles are aligned to the forward strand of NCBI Build 36.
b
Weighted mean frequency of T2D risk allele across Stage 2 studies.